𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: Clinical and cytokinetic results

✍ Scribed by P F Conte; A. Alama; G. Bertelli; G. Canavese; F Carnino; A. Catturich; E Di Marco; G. Gardin; A. Jacomuzzi; C. Monzeglio; C. Mossetti; A. Nicolin; P. Pronzato; R. Rosso

Publisher
John Wiley and Sons
Year
1987
Tongue
French
Weight
528 KB
Volume
40
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Thirty-nine patients with locally advanced breast cancer (T~b.4, N1-3 or inflammatory carcinoma) received 3 cycles of induction chemotherapy with estrogenic recruitment before surgery. The therapeutic regimen consisted of diethylstilbestrol (DES) orally on days 1-3, 5-Fluorouracil + Doxorubicin + Cyclophosphamide on day 4 q 21 days (DES-FAC). After surgery 6 additional cycles of chemotherapy (3 DES-FAC alternating with 3 DES-CMF with Methotrexate + F and C as in FAC) were administered. The objective response rate was 71.8% with 15.4010 CR. and 56.4% PR; after surgery 36/39 (92.3%) patients were rendered disease-free. So far, 13 of 26 patients in stage lllb have relapsed (9 of 13 with inflammatory carcinomas). Three-year survival and progression-free survival are 60% and 53.5010, respectively. Twenty-three of the 39 patients were subjected to serial tumor biopsies during the first DES-FAC regimen to allow for tumor-cell kinetic studies during DES and chemotherapy. A significant estrogenic recruitment occurred in 16 patients (69.6%). irrespective of estrogen-receptor status. A t surgery, 3-4 weeks after induction chemotherapy, tumor proliferative activity was significantly depressed in comparison to basal values. These results indicate that breast cancer cells can be recruited in vivo with DES and that chemotherapy following estrogenic stimulation is effective and feasible with acceptable toxicity.

πŸ“œ SIMILAR VOLUMES

Use of radioimmunoguided surgery after i
Use of radioimmunoguided surgery after induction chemotherapy in locally advanced breast cancer
✍ Fausto Badellino; Sergio Bertoglio; Giuliano Mariani; Paolo Meszaros; Giuseppe C πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 47 KB πŸ‘ 2 views

Twenty-one patients with histologically proven locally advanced breast cancer (LABC) were treated with a combined modality approach based on primary chemotherapy and radical modified mastectomy followed by adjuvant chemotherapy. Surgery was performed by using radioimmunoguided surgery (RIGS) techniq

Hormonal receptors in locally advanced b
Hormonal receptors in locally advanced breast cancer: Change with response to neoadjuvant chemotherapy?
✍ Don M. Morris; Jackie Edwards; Frank Gelder πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 225 KB πŸ‘ 1 views

## Abstract Twenty‐one cancers in 20 patients with locally advanced breast cancer were studied. Incisional biopsy was performed without using electrocautery. Tissue was obtained for histology and estrogen (ER) and progesterone (PR) receptors. Patients received chemotherapy after biopsy. All respond

Predicting survival and early clinical r
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI
✍ Roar Johansen; Line R. Jensen; Jana Rydland; PΓ₯l E. Goa; Kjell A. Kvistad; Tone πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 990 KB

## Abstract ## Purpose To evaluate dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) as a tool for early prediction of response to neoadjuvant chemotherapy (NAC) and 5‐year survival in patients with locally advanced breast cancer. ## Materials and Methods DCE‐MRI was performed in pa